수의 종양학 시장 : 비즈니스 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Veterinary Oncology Market was valued at USD 2 billion in 2025 and is estimated to grow at a CAGR of 10.3% to reach USD 5.4 billion by 2035.

Growth is reinforced by expanding pet ownership, higher spending on animal healthcare, and a steadily broadening pipeline of veterinary oncology drugs and diagnostics. As pets live longer due to improved preventive care, the incidence of age-related cancers is also rising, directly expanding the treated patient pool. At the same time, growing willingness among pet owners to pursue active cancer therapies rather than purely supportive care is reshaping treatment expectations. Advances in diagnostic imaging, such as CT, MRI, and digital radiography, combined with molecular testing and minimally invasive biopsy tools, are enabling earlier detection and more precise treatment planning. Lower equipment costs are also allowing general veterinary clinics to adopt oncology screening capabilities, widening access beyond specialized centers.

The diagnostics segment accounted for 43.9% share in 2025 and is projected to grow at a CAGR of 10.4% through 2035. Its expansion reflects the increasing use of advanced imaging and laboratory-based diagnostic tools across both specialty hospitals and well-equipped general veterinary practices. Imaging technologies remain the primary revenue contributor, supported by CT, MRI, ultrasound, and digital radiography systems used for tumor detection, staging, and treatment planning. Minimally invasive procedures such as ultrasound-guided sampling are also improving diagnostic accuracy while reducing patient risk, further supporting segment growth.

The lymphoma segment held a 27.4% share in 2025 and will grow at a CAGR of 10.8% through 2035. Canine lymphoma remains the most diagnosed form and is categorized into multicentric, alimentary, mediastinal, and extranodal types, with aggressive multicentric cases being the most frequently observed. Standard treatment practices are largely based on multi-agent chemotherapy protocols adapted from human oncology, which continue to deliver strong remission outcomes and extended survival periods in treated animals.

North America Veterinary Oncology Market held a 49.8% share and is projected to grow at a CAGR of 10.1% through 2035. The region's leadership is supported by a highly developed veterinary healthcare ecosystem, strong availability of specialist oncologists, and a regulatory framework that supports veterinary drug innovation and approvals. The United States remains the central market, backed by leading academic and referral institutions that contribute significantly to clinical research, treatment innovation, and the advancement of oncology care standards.

Major players operating in the global veterinary oncology market include Zoetis Inc., Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, Merck Animal Health, AB Science S.A., IDEXX Laboratories, Inc., Siemens Healthineers (Varian Medical Systems), Accuray Incorporated, Elekta AB, PetCure Oncology, Virbac S.A., Dechra Pharmaceuticals PLC, and Nippon Zenyaku Kogyo Co., Ltd. (ZENOAQ). Companies in the veterinary oncology market are strengthening their position through expanded investment in drug development pipelines focused on targeted and immuno-oncology therapies designed specifically for companion animals. Strategic collaborations between pharmaceutical firms and veterinary research institutions are accelerating clinical validation and product approvals. Players are also enhancing diagnostic-treatment integration by combining imaging, molecular testing, and therapeutic solutions into unified oncology care pathways. Geographic expansion through specialty clinics and referral networks is improving treatment accessibility across emerging urban markets. Digital health platforms and tele-oncology services are being deployed to support remote consultation and treatment monitoring.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Market estimates & forecasts parameters
• 1.8 Forecast model
  • 1.8.1 Quantified market impact analysis
    • 1.8.1.1 Mathematical impact of growth parameters on forecast
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
  • 2.1.1 Business trends
  • 2.1.2 Cancer diagnostics & treatment trends
  • 2.1.3 Animal type trends
  • 2.1.4 Cancer type trends
  • 2.1.5 Regional trends
• 2.2 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence and incidence of cancer in animals
    • 3.2.1.2 Technological advancements in pet cancer diagnosis
    • 3.2.1.3 Growing research and investments in pet cancer therapy
    • 3.2.1.4 Increasing pet insurance adoption
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of cancer treatment and procedures
    • 3.2.2.2 Adverse effects of drugs used for pet cancer treatment
  • 3.2.3 Market opportunities
    • 3.2.3.1 Development of personalized and targeted oncology therapies
    • 3.2.3.2 Expansion of veterinary oncology infrastructure and specialty clinics
• 3.3 Growth potential analysis
• 3.4 Technology and innovation landscape
  • 3.4.1 Current technological trends
  • 3.4.2 Emerging technologies
• 3.5 Pricing trend analysis (Driven by primary research)
• 3.6 Regulatory landscape (Driven by primary research)
  • 3.6.1 North America
  • 3.6.2 Europe
  • 3.6.3 Asia Pacific
  • 3.6.4 Latin America
  • 3.6.5 MEA
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Patent analysis
• 3.10 Future market trends
• 3.11 Impact of AI and Generative AI on the market (Driven by primary research)
• 3.12 Investment & funding analysis (Driven by primary research)
• 3.13 Pet population statistics (Driven by primary research)

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Cancer Diagnostics & Treatment, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Diagnostics
  • 5.2.1 By Type
    • 5.2.1.1 Imaging
    • 5.2.1.2 Biopsy
    • 5.2.1.3 Endoscopy
    • 5.2.1.4 Other diagnostics
  • 5.2.2 By End Use
    • 5.2.2.1 Veterinary hospitals & clinics
    • 5.2.2.2 Diagnostics centers
    • 5.2.2.3 Other end users
• 5.3 Treatment
  • 5.3.1 By Type
    • 5.3.1.1 Surgery
    • 5.3.1.2 Radiotherapy
    • 5.3.1.3 Chemotherapy
    • 5.3.1.4 Immunotherapy
    • 5.3.1.5 Other treatments
  • 5.3.2 By End Use
    • 5.3.2.1 Veterinary hospitals
    • 5.3.2.2 Veterinary clinics
    • 5.3.2.3 Other end users

Chapter 6 Market Estimates and Forecast, By Animal Type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Canine
• 6.3 Feline
• 6.4 Equine
• 6.5 Other animal types

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Mast cell tumors
• 7.3 Mammary tumors
• 7.4 Lymphomas
• 7.5 Melanoma
• 7.6 Other cancer types

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 France
  • 8.3.3 UK
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Zoetis Inc.
• 9.2 AB Science S.A.
• 9.3 Elanco Animal Health Incorporated
• 9.4 Boehringer Ingelheim International GmbH
• 9.5 Merck Animal Health (Merck & Co., Inc.)
• 9.6 IDEXX Laboratories, Inc.
• 9.7 Siemens Healthineers (Varian Medical Systems)
• 9.8 Accuray Incorporated
• 9.9 Elekta AB
• 9.10 PetCure Oncology
• 9.11 Virbac S.A.
• 9.12 Dechra Pharmaceuticals PLC
• 9.13 Nippon Zenyaku Kogyo Co., Ltd. (ZENOAQ)